TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04053582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AMT
Description: The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 3 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: The session will be done on an individual basis. Sham group will receive artificial neurofeedback while focusing on the physical sensations of the breath. The session will last one hour, including 3 sham neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with artificial neurofeedback (70s).
Study: NCT05677399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic exercise and peloidotherapy
Description: Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
Study: NCT03352284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann Pure Ceramic Implant
Description: The surgical technique begins with the lift of a vestibular mucoperiosteal flap respecting the papillae of the adjacent teeth. After the alveolar bone is exposed, the sequence of drilling and placement of the intra-bone fixation are carried out. In case of fenestrations or dehiscence, they are treated by xenograft and collagen-absorbable membrane. Once the implant is placed, a healing cap or provisional prosthesis is placed depending on the torque achieved. Finally, the flap is replaced and sutured.
Study: NCT02978469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life style changing: reducing sedentary behavior
Description: The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life style changing: reducing sedentary behavior
Description: The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities.
Study: NCT01849614

Intervention type: OTHER
Intervention: Cardiac SPECT perfusion scan
Description: A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
Study: NCT02667639

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RPH-104
Description: Anti-IL-1 Mab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride Sterile Injection 0.9% w/v
Description: Sterile saline solution
Study: NCT03777241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention Team
Description: Multidisciplinary team to assist with actively identifying and managing mental illness and substance abuse disorders at their earliest possible time during hospitalization.
Study: NCT05623176

Intervention type: OTHER
Intervention: Standardised laparotomy care
Description: This is a cohort study and no intervention as part of the study has been introduced. We are studying two groups and comparing the two before and after the introduction of a standardised laparotomy care protocol as part of a clinical quality improvement measure.
Study: NCT00386282

Intervention type: DRUG
Group type: OTHER
Intervention: mifepristone-misoprostol treatment
Description: 200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
Study: NCT04695912

Intervention type: DEVICE
Group type: OTHER
Intervention: The SENS motion® sensor
Description: The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity.

Intervention type: DEVICE
Group type: OTHER
Intervention: The SENS motion® sensor
Description: The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity.
Study: NCT00976872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3
Description: omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
Study: NCT03777241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants in this group will receive standard of care.
Study: NCT03567096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiV pacing with MPP and SyncAV
Description: This cohort will receive Bi-Ventricular Pacing (left ventricle and right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
Study: NCT02398240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days: 2 and 16 Dose: 375 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days: 2 and 16 Dose: 375 mg/m2/dose.
Study: NCT00984308

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)
Description: Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)
Description: Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
Study: NCT06173583

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection/screening
Description: Using ARISCAT and LAS VEGUS risk scores for predicting PPCs
Study: NCT03697642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With nasopharyngeal airway
Description: Nasopharyngeal airway is previously inserted into selected nostril. NG tube is properly lubricated and placed through Nasopharyngeal airway.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without nasopharyngeal airway
Description: NG tube is properly lubricated and placed into selected nostril
Study: NCT02405156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Study: NCT01620229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04486651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Injection
Description: 160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan Hydrochloride Injection
Description: 160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as IV infusion on Day 1 of each 21-day cycle.
Study: NCT02413853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP/beta-catenin Antagonist PRI-724
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02799264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg
Description: Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg
Description: Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.
Study: NCT02468219

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cardiovascular rehabilitation program
Description: Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).~Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).~Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cardiovascular rehabilitation program
Description: Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).~Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).~Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training.
Study: NCT04554524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy+Pembrolizumab.
Description: Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). After 4 cycles treatment, complete response subjects continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, some of partial disease and stable disease subjects can receive surgical treatment. And then continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, other partial disease and stable disease subjects cannot be removed by surgery will continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab for 4 cycles and then pembrolizumab or Normal Saline up to disease progression.
Study: NCT01948700

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Study: NCT04187807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 5 mg
Description: Placebo
Study: NCT00223639

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topiramate
Description: 200mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 200mg twice a day
Study: NCT00544310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti adhesion agent
Description: Adhesions prevention
Study: NCT04312334

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.
Study: NCT03567096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LV only pacing with MPP and SyncAV
Description: This cohort will receive left ventricular only pacing (no right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
Study: NCT03889288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical device - electronic-pain killer
Description: Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.
Study: NCT00021242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Continuous IV infusion
Study: NCT00742937

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin A
Description: second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: second capsule with vitamin E, eight days after delivery.
Study: NCT04194112

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: immediate urine cytology
Description: Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
Study: NCT01707524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Randomized left versus right radial artery approach
Description: Randomized left versus right radial artery approach
Study: NCT01805999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7 g Ispaghula

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 7 g placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3.5g Ispaghula + 3.5 g placebo
Study: NCT04210518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: This intervention consisted of a supervised multimodal exercise protocol addressing different aspects of balance including static and dynamic tasks on the injured ankle. The training program comprised 6 exercises that were progressively adapted depending on the patient's execution controlled by an expert physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stroboscopic glasses
Description: Patients included in this group performed the same protocol described in the balance training group with the addition of the stroboscopic glasses during the intervention.
Study: NCT00540917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cooling spray during laser treatment
Description: skin temperature measurement
Study: NCT03534674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
Study: NCT01687660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: apply acupuncture to prevent the migraine attack

Intervention type: OTHER
Group type: OTHER
Intervention: acupuncture
Description: apply acupuncture to prevent the migraine attack
Study: NCT03530696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is to be taken orally on days 5-18 (14 days) of each cycle (each cycle length is 21 days). The starting dose will be 125mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: The recommended dose of T-DM1 is 3.6 mg/kg and is given as an intravenous infusion on Day 1 of every cycle (every 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: The recommended dose of T-DM1 is 3.6 mg/kg and is given as an intravenous infusion on Day 1 of every cycle (every 21 days).
Study: NCT00484510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vitamin C)
Description: Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
Study: NCT03915743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care
Description: complex and multi-faceted individualized palliative care
Study: NCT03199690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Antiviral (integrase inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Antibiotic
Study: NCT04524156

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physiology
Description: Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiology
Description: Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method).
Study: NCT00658853

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 times 4 minutes high aerobic intensity one leg cycling
Description: 3 times per week for 10 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 times 4 minutes high aerobic intensity one leg cycling
Description: 3 times per week for 10 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 times 4 minutes high aerobic intensity one leg cycling
Description: 3 times per week for 10 weeks